|
May 6
|
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
|
|
Apr 11
|
Oncolytics Up 1.5% in U.S. Pre-market as Funds Pelareorep's Ongoing Clinical Development
|
|
Apr 10
|
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
|
|
Apr 10
|
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
|
|
Feb 25
|
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
|
|
Feb 14
|
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
|
|
Jan 1
|
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?
|
|
Oct 7
|
ONCY Stock Up on Regulatory Update From Breast Cancer Program
|
|
Oct 7
|
Oncolytics targets accelerated approval for oncolytic virus therapy
|
|
Jul 24
|
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
|
|
Jun 24
|
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
|
|
Jun 21
|
Oncolytics doses first subject in pancreatic cancer trial
|
|
Jun 20
|
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
|
|
Jan 9
|
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
|
|
Dec 7
|
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
|
|
Sep 8
|
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
|
|
Sep 7
|
Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
|
|
Sep 6
|
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Jun 22
|
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
|